Article info

Download PDFPDF

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

Authors

  • Mizuki Nishino Department of RadiologyBrigham and Women’s Hospital and Dana-Farber Cancer Institute 450 Brookline Ave 02215 Boston MA USA PubMed articlesGoogle scholar articles
  • Maria Gargano Department of Medical Oncology and Department of MedicineDana-Farber Cancer Institute and Brigham and Women’s Hospital 450 Brookline Ave 02215 Boston MA USA PubMed articlesGoogle scholar articles
  • Margaret Suda Department of Medical Oncology and Department of MedicineDana-Farber Cancer Institute and Brigham and Women’s Hospital 450 Brookline Ave 02215 Boston MA USA PubMed articlesGoogle scholar articles
  • Nikhil H Ramaiya Department of RadiologyBrigham and Women’s Hospital and Dana-Farber Cancer Institute 450 Brookline Ave 02215 Boston MA USA PubMed articlesGoogle scholar articles
  • F Stephen Hodi Department of Medical Oncology and Department of MedicineDana-Farber Cancer Institute and Brigham and Women’s Hospital 450 Brookline Ave 02215 Boston MA USA PubMed articlesGoogle scholar articles
  1. a Mizuki_Nishino{at}dfci.harvard.edu
  2. b mgarga08{at}gmail.com
  3. c MargaretASuda{at}gmail.com
  4. d NR988{at}partners.org
  5. e Stephen_Hodi{at}dfci.harvard.edu
View Full Text

Citation

Nishino M, Gargano M, Suda M, et al
Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

Publication history

  • Received March 12, 2014
  • Accepted April 16, 2014
  • First published June 18, 2014.
Online issue publication 
February 09, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.